title: Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin.
abstract: Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system characterized by plaque formation containing lost oligodendrocytes, myelin, axons, and neurons. Remyelination is an endogenous repair mechanism whereby new myelin is produced subsequent to proliferation, recruitment, and differentiation of oligodendrocyte precursor cells into myelin-forming oligodendrocytes, and is necessary to protect axons from further damage. Currently, all therapeutics for the treatment of multiple sclerosis target the aberrant immune component of the disease, which reduce inflammatory relapses but do not prevent progression to irreversible neurological decline. It is therefore imperative that remyelination-promoting strategies be developed which may delay disease progression and perhaps reverse neurological symptoms. Several animal models of demyelination exist, including experimental autoimmune encephalomyelitis and curprizone; however, there are limitations in their use for studying remyelination. A more robust approach is the focal injection of toxins into the central nervous system, including the detergent lysolecithin into the spinal cord white matter of rodents. In this protocol, we demonstrate that the surgical procedure involved in injecting lysolecithin into the ventral white matter of mice is fast, cost-effective, and requires no additional materials than those commercially available. This procedure is important not only for studying the normal events involved in the remyelination process, but also as a pre-clinical tool for screening candidate remyelination-promoting therapeutics.
authors: Department of Clinical Neurosciences, Hotchkiss Brain Institute at University of Calgary.
authors: Michael B
authors: MB
authors: Keough
authors: Department of Clinical Neurosciences, Hotchkiss Brain Institute at University of Calgary.
authors: Samuel K
authors: SK
authors: Jensen
authors: Department of Clinical Neurosciences, Hotchkiss Brain Institute at University of Calgary; Department of Oncology, Hotchkiss Brain Institute at University of Calgary; vyong@ucalgary.ca.
authors: V Wee
authors: VW
authors: Yong
mesh_terms: D000818:Animals; D001369:Axons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D005260:Female; D008244:Lysophosphatidylcholines / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D009186:Myelin Sheath / Q000378:metabolism* / Q000473:pathology; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
chemical_list: D008244:Lysophosphatidylcholines